Several trials have tried for decades to improve the outcome of extensive disease small cell lung cancer (ED-SCLC) through attempts to modify the standard treatments. Nevertheless, platinum/etoposide combination and topotecan have remained respectively the first and the second line standard treatments for the last 40 years. With the advent of immunotherapy, this scenario has finally changed. Our review aims to provide an overview of the primary studies on the actual therapeutic strategies available for ED-SCLC patients, and to highlight emerging evidence supporting the use of immunotherapy in SCLC patients.
- Lazzari, C.
- Mirabile, A.
- Bulotta, A.
- Viganó, M. G.
- Ogliari, F. R.
- Ippati, S.
- DellOca, I.
- Santarpia, M.
- Lorusso, V.
- Reck, M.
- Gregorc, V.
Keywords
- Immunotherapy
- chemotherapy
- extensive disease
- small cell lung cancer
